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Abstract
The efficient synthesis of an 80-member library of unique benzoxathiazocine 1,1-dioxides by a microwave-assisted, intermolecular
nucleophilic aromatic substitution (SNAr) diversification pathway is reported. Eight benzofused sultam cores were generated by
means of a sulfonylation/SNAr/Mitsunobu reaction pairing protocol, and subsequently diversified by intermolecular SNAr with ten
chiral, non-racemic amine/amino alcohol building blocks. Computational analyses were employed to explore and evaluate the
chemical diversity of the library.
Introduction
The demand for functionally diverse chemical libraries has
emerged, as rapid advances in the fields of genomics and
proteomics during the “post-genome era” have resulted in an
increase in potential therapeutic targets for which there are no
known small-molecule modulators [1]. The lack of adequate
screening technologies, as well as screening collections of
molecules, has hindered these efforts [2,3]. In this regard, recent
advances in the construction of chemical libraries that are rich
in functional diversity, consisting of appendage, functional
group, stereochemical and skeletal diversity, have addressed
this challenge and also offer new opportunities [4].
Sultams (cyclic sulfonamides) represent a class of compounds
with a non-natural chemotype [5,6] that have gained enormous
interest in recent years due to their extensive range of bio-
logical activities [7-14]. In particular, benzofused sultams,
possessing a rich content of sp3 amine functionality, have
shown a wide biological profile, including antipsychotic activity
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Figure 1: Biologically active benzofused sultams.
Scheme 1: Proposed library generation by microwave-assisted intermolecular SNAr diversification reaction.
[15], modulation of histamine H3-receptor [16], glucokinase ac-
tivation [17,18] and allosteric modulation of AMPA receptor
[19], to name but a few (Figure 1). While there are numerous
methodologies being reported in the literature for the synthesis
of 5-, 6- and 7-membered benzofused sultams, reports on the
generation of 8-membered benzofused sultams have been sparse
[20-22]. In this regard, our group has focused on the develop-
ment of several methodologies and protocols for the generation
of diverse sultam collections [23-26]. Recent highlights towards
these goals include, “click-click-cyclize” [27,28], complemen-
tary ambiphile pairing (CAP) [29], and reagent-based DOS
[30,31]. In 2011, we reported the development and application
of an efficient reaction pairing strategy utilizing three simple
reactions, namely sulfonylation, Mitsunobu alkylation and
SNAr, which when combined in different sequences or with
different coupling reagents, give access to skeletally diverse
sultams, including the title compounds and the 8-membered
bridged, benzofused sultams [32]. Building on this strategy, we
herein report the design and synthesis of an 80-member library
of benzofused sultams by a microwave-assisted, intermolecular
SNAr diversification of core benzoxathiazocine 1,1-dioxide
scaffolds [33-36] (Scheme 1).
Results and Discussion
Initial efforts focused on the synthesis of eight core scaffolds
1–8 on multigram scale through the use of three efficient steps,
namely sulfonylation, Mitsunobu alkylation and SNAr, to
generate both stereoisomers of each core [37] (Scheme 2). The
bridged benzofused sultam scaffolds were prepared by a
sulfonylation intramolecular SNAr protocol, reported previ-
ously [32], utilizing 3-hydroxypyrrolidine in combination with
2,4-difluoro- and 2,6-difluorobenzenesulfonyl chloride. The
nonbridged scaffolds were also prepared as reported previously
by a sulfonylation intermolecular Mitsunobu alkylation/
intramolecular SNAr protocol [32]. 2,4-Difluoro- and 2,6-
difluorobenzenesulfonyl chloride were sulfonylated with cyclo-
propyl amine followed by Mitsunobu alkylation with 3-silyl-
oxybutan-1-ol and subsequent one-pot desilylation intramolec-
ular SNAr alkoxylation (Scheme 2). Each of the scaffolds 1–8
was prepared on a 2.5 g scale.
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Scheme 2: Utilization of a reaction pairing strategy for the synthesis of benzoxathiazocine 1,1-dioxides core scaffolds 1–8.
Table 1: Optimization studies for the SNAr reaction utilizing sultam 4.
Entry Amine Equiv Base Conc. (M) Time (min) Temp (°C) Yielda (%)
1 (R)-3-pyrrolidinol 1.3 Cs2CO3 0.1 30 150 NA
2 (R)-3-pyrrolidinol 4.4 — 0.1 20 150 94
3 (S)-2-pyrrolidine methanol 4.4 — 0.1 30 150 29
4 (S)-2-methoxymethyl pyrrolidine 4.3 — 0.1 50 180 NA
5 (S)-3-dimethylamino pyrrolidine 5.0 — 0.1 50 180 88
6 (R)-2-methylpyrrolidine 5.0 — 0.1 30 150 42
7 (R)-2-methylpyrrolidine 5.0 — 0.1 40 180 62b
8 (R)-2-methylpyrrolidine 5.0 — 0.1 50 180 70
9 (R)-2-methylpyrrolidine 5.0 — 0.1 60 180 35
10 (R)-2-methylpyrrolidine 5.0 — 0.5 50 180 95b
11 (R)-2-methylpyrrolidine 5.0 — 1.0 50 180 83b
aYields are reported after flash column chromatography on silica gel. bCrude yield as judged by 1H NMR.
With scaffolds 1–8 in hand, efforts were focused on the diversi-
fication of these core scaffolds with a variety of chiral, non-
racemic amines/amino alcohols, by intermolecular SNAr
utilizing benzoxathiazocine 1,1-dioxide 4 as the test substrate
(Table 1). A variety of reaction conditions (equiv of amine,
presence of base, concentration of solvent, time and tempera-
ture) were examined to identify the optimal conditions. Our
initial attempt gave a good yield of 94% with 4.4 equiv of
amine, an absence of base, at a concentration of 0.1 M of
DMSO, and under microwave irradiation at 150 °C for 20 min
(Table 1, entry 2). However, when a hindered amine was
utilized it resulted in low (29%) or no yield, even when the
reaction time was extended (Table 1, entry 3) or when slightly
harsher conditions were used (Table 1, entry 4). Thus, more
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Figure 2: Benzoxathiazocine 1,1-dioxides 1–8 and amine library building blocks {1–10}.
experiments were performed to investigate other factors, in
which the nature and equiv of amine remained the same while
the concentration of solvent, temperature and reaction time
were increased. Finally, the optimal results were obtained in the
absence of base, with 5 equiv of amine, at a concentration of
0.5 M in DMSO, and under 50 min of microwave irradiation at
180 °C (Table 1, entry 10). All reactions were performed under
identical conditions, thus attempts were not made to optimize
the conditions further for individual substrates.
Library design
An 80-member, full matrix library was designed by using in
silico analysis [38]. Eight benzoxathiazocine 1,1-dioxide scaf-
folds 1–8 were designed, of which library I (1–4) was
composed of the entire spectrum of possible stereoisomers, and
library II (5–8) was composed of two sets of benzofused
sultams having an H or Me group at the R1 position. The use of
all possible stereoisomers provides the opportunity to generate
stereochemical SAR (SSAR) for each building block combina-
tion. With the core sultams in hand, a virtual library incorpor-
ating all possible combinations of the building blocks of the
secondary amines {1–10} was constructed for each scaffold
(Figure 2). Physico-chemical property filters were applied,
guiding the elimination of undesirable building blocks that led
to products with undesirable in silico properties (see Supporting
Information File 1 for full in silico data and detailed informa-
tion on the calculations). These metric filters included standard
Lipinski’s rule of five parameters (molecular weight <500,
ClogP <5.0, number of H-acceptors <10, and number of
H-donors <5), in addition to consideration of the number of
rotatable bonds (<5) and polar surface area. Absorption, distrib-
ution, metabolism and excretion (ADME) properties were
calculated by using the Volsurf program [39]. Cartesian grid-
based chemical diversity analysis was performed according to
the method described previously [40], by using standard
H-aware 3D BCUT descriptors comparing against the MLSMR
screening set (ca. 7/2010; ~330,000 unique chemical
structures). Guided by this library design analysis, benzoxathia-
zocine 1,1-dioxides scaffolds 1–8 and amines {1–10} were
chosen to generate the aforementioned 80-member library.
Validation and library generation
With the optimized conditions in hand, a 20-member validation
library was prepared by using scaffolds selected from 1–5 and
amines {1–10} in DMSO (0.5 M) at 180 °C for 50 min, in
1 dram vials, using the Anton Parr Synthos 3000® platform
(Table 2) [41]. Upon completion, the crude reaction mixtures
were diluted, filtered through silica SPE, and purified by auto-
mated mass-directed HPLC. Library validation was essential to
assess both substrate and reaction scope, along with evaluating
the application of automated mass-directed HPLC as the final
analysis and purification method. Key goals for this compound
collection were the synthesis of compounds in >90% purity in
40–50 mg quantities, which would be sufficient for HTS
screening in the Molecular Library Probe Center Network
(MLPCN) (20 mg), for external biological outreach screening
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Table 2: Use of a 20-member validation library to probe the reaction scope.
Sultama Purity (%)b Yield (%)b Quantity (mg) Sultama Purity (%)b Yield (%)b Quantity (mg)
1{3} 99.8 78 79.5 5{1} 100 80 79.8
2{3} 99.4 69 70.0 5{2} 100 80 79.4
3{3} 100 48 49.3 5{3} 100 76 75.8
4{3} 99.7 53 54.1 5{4} 100 79 79.1
1{1} 100 71 71.7 5{5} 100 83 85.7
1{2} 100 72 73.4 5{6} 100 80 83.1
1{4} 99.8 75 76.7 5{7} 98.2 17 18.7c
1{5} 99.7 69 73.6 5{8} 99.9 46 49.2
1{6} 99.6 85 90.2 5{9} 99.1 79 85.3
1{8} 100 86 94.9 5{10} 99.1 78 83.7
aReaction conditions: benzoxathiazocine 1,1-dioxides 1–8 (1 equiv, 80 mg), dry DMSO (0.5 M) and amine (5 equiv.); bpurified by automated prepara-
tive reverse phase HPLC (detected by mass spectroscopy); purity was assessed by HPLC (214 nm); cthe low yield obtained was due to instrumental
error (see Supporting Information File 1 for more information).
partners (20 mg), and to retain a sample (10 mg) for follow-up
evaluation or to resupply the NIH MLPCN. Evaluation of this
validation library demonstrated that all 20 members were
successfully prepared (average purity = 99.7%, yield = 70%,
quantity = 73.0 mg) in the desired sultam final masses, with all
20 possessing a final purity >98%.
With the validation completed, the remaining 60 compounds of
both libraries I and II were synthesized by the diversification of
core benzoxathiazocine 1,1-dioxides scaffolds 1–8 and amine
{1–10}. Under the optimal SNAr reaction conditions, libraries I
and II were generated and purified by automated mass-directed
HPLC. A total of 80 compounds were prepared and isolated in
good yields (average yield 65%), and all compounds had puri-
ties greater than 95% after automated purification (see
Supporting Information File 1 for all compounds with full
numeric data). Final assessment of both libraries I and II
demonstrated that the primary objectives set out in the library
design were achieved; final masses ranged between 18–127 mg
and the average final mass was 68 mg (original target being
50 mg).
In silico analysis of chemical diversity and
drug-likeness
In silico analysis of the molecular library was performed to
achieve enhanced drug-like and lead-like properties, as well as
to assess the molecular diversity. In order to assess diversity,
five computational analyses were performed, including
1. Cartesian grid-based chemical diversity analysis [40]
2. Overlay analysis
3. Principal moments of inertia (PMI) analysis [42]
4. Conformational analysis
5. Quantitative estimate of drug-like (QED) values [43]
Cartesian grid-based chemical diversity analysis
The grid-based diversity analysis protocol, described previ-
ously in the Library Design section, provides a simple measure
of the relative novelty of a compound. By computing the pos-
ition of a compound within the molecular property space
defined by a large reference set of other interesting compounds,
chemical novelty can be estimated from the density of refer-
ence compounds in close proximity to the compound of interest.
Beilstein J. Org. Chem. 2012, 8, 1293–1302.
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Figure 3: (i) Simple cartoon of the library compounds, with a core of MW ~ 80, based on Lipinski’s rules (MW < 500), and comprising three
substituents, each having MW < 140, to establish different functional groups. (ii) This cartoon demonstrates that the substituents extend out of the
core in a circular motion. (iii) Overlay images exhibiting the common core in these 80 compounds. (iv) and (v) both overlay images revealing that the
substituents are extending outwards in the circular motion as mentioned in (ii).
This analysis suggests that our compounds consistently occupy
regions of chemical space that are under-represented within the
MLSMR reference set. Specifically, all 80 compounds were
located in regions with local compound densities of less than
the mean value, with compounds 3{3}, 4{3}, 4{4}, 5{3} and
5{4} occupying a particularly sparse region of space (all colo-
cating within a cell whose density was 3.5% of the mean
density experienced by the reference compounds), while the
least unique eight compounds (5{5}, 5{6}, 7{3}, 7{4}, 7{5},
7{6}, 8{3} and 8{4}) all colocated in a cell with density equal to
78.9% of the mean density experienced by the reference com-
pounds. The mean local density experienced by the 80 com-
pounds reported herein was only 31.7% of the mean density
experienced by the reference compounds. All related informa-
tion can be found in Supporting Information File 1.
Overlay analysis
The overlay produced for the 80 compounds reported herein is
depicted in Figure 3 and provides a rudimentary indication of
the shape distribution and diversity evident in this library.
Orientations 3iv and 3v collectively suggest that the library gen-
erally tends toward elongated (rod-like) structures, while the
apparent distribution of functional substituents across angles
spanning the better part of the whole sphere surrounding the
conserved core, suggests that the library as a whole achieves a
reasonable level of shape-based diversity.
Principal moments of inertia (PMI) analysis
The rudimentary information gleaned from overlay analysis can
be quantified more rigorously via principal moments of inertia
(PMI) analysis, which was also employed herein to assess the
molecular diversity [42]. PMI analysis utilizes shape-based
descriptors: The minimum energy conformation of each library
member is determined, PMI ratios are calculated and normal-
ized, and a subsequent triangular plot depicts the shape diver-
sity of the library. The analysis reveals that the 80 compounds
generally mirror the shape distribution of the set of 771 known
drugs (Figure 4), thus demonstrating the potential drug-likeness
of our scaffold. In contrast, some of the compounds are located
in the unpopulated region of chemical space, illustrating the
novel nature of some of our compounds from the perspective of
molecular shape.
Conformational analysis
While overlay and PMI analysis tend to focus on the shape
diversity of libraries as a function of the combined structure of
Beilstein J. Org. Chem. 2012, 8, 1293–1302.
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Figure 4: Distribution of 80 compounds (colored spheres) relative to the set of 771 known orally available drugs (black dots) [43].
Figure 5: Comparison of a small set of our representative compounds versus two sultams synthesized by our group as well as a biological active
compound [11].
the core scaffold and all known substituents, it is useful to quan-
tify the conformational diversity of the core alone, since this
provides additional insight into the prospects for sampling new
diversity space as a function of hitherto untested substituents.
To quantify this, computations were generated for the mean
pairwise atomic root-mean-squared distance (RMSD) using a
small set of representative products from the library that was
synthesized and compared this value with similar pairwise
RMSD calculations for other analogous libraries (Figure 5). In
all cases, the structures have been sketched and optimized in
SYBYL [44], according to default molecular mechanics
settings, and the resulting optimized structures were then all
mutually aligned in order to minimize the total pairwise RMSD
among conserved scaffold core atoms. The pairwise RMSD
values reported in Figure 5 also only correspond to conserved
core atoms. The fact that the highlighted core scaffold achieves
Beilstein J. Org. Chem. 2012, 8, 1293–1302.
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a much higher RMSD than the other libraries suggests that the
scaffold conformation is more sensitive to the choice of
substituents, whereas the other libraries exhibit little variation
as a function of different substituents. This greater sensitivity on
the part of the highlighted library should correspond to greater
conformational diversity, which implies sampling of a broader
range of property and pharmacophore space than those libraries
with lesser conformational diversity.
Quantitative estimate of drug-like (QED) values and
Z-scores
While molecular diversity is in itself a topic of intellectual
value, in applied sciences it is important to balance this intellec-
tual aspect with suitability toward the intended application. In
other words, if one intends to synthesize novel compounds for
potential pharmacological applications it is critical that the com-
pounds not only be unique but also be drug-like. Quantifying
drug-likeness is one of the numerous methods that are regularly
utilized as useful guidelines for early stage drug discovery. A
measure of drug-likeness based on the concept of desirability
called the quantitative estimate of drug-likeness (QED) has
been proposed [43]. The QED concept is a simple approach to
multicriteria optimization whereby compound desirability is
defined as a function of eight molecular properties, i.e., molec-
ular weight, ALogP, polar surface area, H-bond donor,
acceptor, rotatable bond and aryl ring counts, and the presence
of structural alerts. The weighted QED values were calculated
based on the equation provided by Hopkins et al., mapping
compounds to a range from 0 to 1, in which a value of 1 indi-
cates that all properties are within a favorable range. Based on
this measure, the 80 compounds reported herein may have
elevated prospects for interesting chemical biology: the lowest
QED values among these 80 compounds (QED = 0.819 for 1{3}
and 1{4}) are actually significantly above the mean value
(QED = 0.615) for the 771 known drugs analyzed by Hopkins
et al., while several distinct scaffolds within our library
produced QED values of greater than 0.90 (Figure 6).
To characterize the QED scores of our scaffolds relative to the
reference set of 771 known drugs, we computed mean Z-scores
for each scaffold and plotted them in Figure 7. Since Z-scores of
1.64 and 1.0 correspond to percentile rankings of 95 and 84.1,
respectively, it is apparent that all of the reported scaffolds
contain compounds with QED values in the upper 80th to lower
90th percentile. The 80 compounds exhibited an average
Z-score of 1.29, which corresponds to a mean percentile ranking
of 90.
Conclusion
In conclusion, an efficient microwave-assisted intermolecular-
SNAr protocol for the synthesis of an 80-member library of
Figure 6: Three representative compounds with high QED values.
amino benzoxathiazocine 1,1-dioxides has been developed.
Employing a variety of commercially available chiral, non-
racemic amines, the 80-member library of bridged, benzofused,
bicyclic sultams was generated by the microwave assisted-SNAr
diversification at 4-F and 6-F positions. A series of computa-
tional analyses was performed in order to provide pertinent
information that guided the second part of the reaction pairing
strategy, which will be reported in due course. Further computa-
tional analysis revealed that the compounds reported herein
generally occupy underrepresented chemical space relative to
the MLSMR screening set, but are drug-like both in terms of
their distribution in shape space (as compared to a collection of
771 known orally available drugs depicted according to molec-
ular PMI profiles) and according to the QED measure (by which
all of this library of compounds are predicted to be signifi-
cantly more drug-like than the average real drug). Structural
overlays and PMI analysis suggest that the highlighted com-
pounds tend to sample a reasonable array of shape space within
the range between rod-like and disk-like compounds. RMSD
comparisons of a selection of representative structures from this
library suggest that the core scaffold has a greater inherent flex-
ibility than comparable products from other related libraries.
This flexibility can produce libraries with greater molecular
diversity as a function of a fixed number of substituents than is
observed for comparably sized libraries arising from more rigid
scaffolds. It is our hope that the combination of drug-likeness
and inherent molecular diversity evident in this library will
produce products that demonstrate interesting behavior in bio-
logical screening. To gauge these prospects rigorously, these
compounds have been submitted for evaluation of their bio-
logical activity in high-throughput screening assays at the NIH
MLPCN and the results will be reported in due course.
Beilstein J. Org. Chem. 2012, 8, 1293–1302.
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Figure 7: Representation of Z-scores for the 80 compounds.
Supporting Information
Supporting Information File 1
Experimental procedures, tabulated results for all libraries,
and full characterization data for 20 representative
compounds.
[http://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-8-147-S1.pdf]
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